Bouchikhi Fadoua, Anizon Fabrice, Moreau Pascale
Université Blaise Pascal, SEESIB-UMR CNRS 6504, 24 Avenue des Landais, 63177 Aubière Cedex, France.
Eur J Med Chem. 2009 Jun;44(6):2705-10. doi: 10.1016/j.ejmech.2009.01.027. Epub 2009 Feb 5.
In the course of structure-activity relationship studies we were interested in the synthesis of isoindigo and 7'-azaisoindigo derivatives substituted at the N-1 position by a 1-(2,3,4,6-tetra-O-acetyl-beta-D-glucopyranosyl), at the 5'-position by various chains introduced by Sonogashira cross-coupling and substituted or not at the 5-position by a bromine atom. To get an insight into the substitution pattern required for the best biological potencies, their kinase inhibitory potencies and their in vitro antiproliferative activities were evaluated. The derivatives were tested toward four protein kinases (CDK5/p25, GSK3, CK1, Dyrk1A) and their in vitro antiproliferative activity was tested against two human myeloid leukaemia cell lines (K562 and HL60).
在构效关系研究过程中,我们感兴趣于合成在N-1位被1-(2,3,4,6-四-O-乙酰基-β-D-吡喃葡萄糖基)取代、在5'-位通过Sonogashira交叉偶联引入各种链且在5-位被或未被溴原子取代的异吲哚并二酮和7'-氮杂异吲哚并二酮衍生物。为深入了解实现最佳生物学活性所需的取代模式,对它们的激酶抑制活性和体外抗增殖活性进行了评估。这些衍生物针对四种蛋白激酶(CDK5/p25、GSK3、CK1、Dyrk1A)进行了测试,并且针对两种人髓系白血病细胞系(K562和HL60)测试了它们的体外抗增殖活性。